人民卫生出版社系列期刊
ISSN 2096-2738 CN 11-9370/R

中国科技核心期刊（中国科技论文统计源期刊）
2020《中国学术期刊影响因子年报》统计源期刊

新发传染病电子杂志

新发传染病电子杂志 ›› 2023, Vol. 8 ›› Issue (3): 39-43.doi: 10.19871/j.cnki.xfcrbzz.2023.03.008

• 论著 • 上一篇    下一篇

新型冠状病毒灭活疫苗接种者免疫效果的真实世界研究

彭浒萍1, 张志成2, 张丹1, 饶建锋1, 王莉1, 李雪1, 鞠蔚华1, 涂相林1, 王淑梅3, 罗达亚4, 刘卓琦4, 黄艳霞1, 敖琴芳5, 周亚岚6, 陈宏义1   

  1. 1.南昌市第九医院感染一科,江西 南昌 330000;
    2.南昌市第九医院ICU ,江西 南昌 330000;
    3.南昌市第九医院呼吸科,江西 南昌 330000;
    4.南昌大学基础医学院,江西 南昌 330000;
    5.南昌市第九医院检验科,江西 南昌 330000;
    6.南昌市第九医院公共卫生科,江西 南昌 330000
  • 收稿日期:2022-05-18 出版日期:2023-06-30 发布日期:2023-07-20
  • 通讯作者: 陈宏义,Email：chenhongyi8660@163.com
  • 基金资助:
    1.江西省卫健委2022年度科技计划项目（202211523）; 2.南昌市科技局新冠攻关项目资助（202033）

A real-world study of the immunogenicity of inactivated SARS-CoV-2 vaccine

Peng Xuping1, Zhang Zhicheng2, Zhang Dan1, Rao Jianfeng1, Wang Li1, Li Xue1, Ju Weihua1, Tu Xianglin1, Wang Shumei3, Luo Daya4, Liu Zhuoqi4, Huang Yanxia1, Ao Qinfang5, Zhou Yalan6, Chen Hongyi1   

  1. 1. Infectious Diseases Department 1, Nanchang Ninth Hospital, Jiangxi Nanchang 330000, China;
    2. ICU,Nanchang Ninth Hospital, Jiangxi Nanchang 330000,China;
    3. Respiratory Department, Nanchang Ninth Hospital,Jiangxi Nanchang 330000,China;
    4. School of Basic Medical Science-Nanchang University,Jiangxi Nanchang 330000, China;
    5. Laboratory Department,Nanchang Ninth Hospital,Jiangxi Nanchang 330000,China;
    6. Public Health Section,Nanchang Ninth Hospital,Jiangxi Nanchang 330000, China
  • Received:2022-05-18 Online:2023-06-30 Published:2023-07-20

PDF

250

摘要： 目的 研究完成3剂次新型冠状病毒灭活疫苗（简称新冠灭活疫苗）接种者的免疫效果及其相关影响因素。方法 选择2020年12月至2021年10月在南昌市第九医院完成3剂次新冠灭活疫苗接种者,于接种第1剂后3周,第2剂后4周、16周、32周,和第3剂后4周,分别抽取静脉血检测新型冠状病毒中和抗体、IgG和IgM抗体。结果 共纳入参与者874例,男316例,女558例。第1剂后3周,第2剂后4周、16周、32周,第3剂后4周中和抗体阳性率分别为26.2%、86.6%、74.2%、78.2%、98.1%;IgG抗体阳性率分别为25.1%、93.2%、59.3%、45.7%、96.8%。中和抗体定量及IgG抗体定量在第2剂后4周、16周、32周及第3剂后4周均明显高于第1剂后3周（P<0.0001）;第2剂后16周、32周均明显低于第2剂后4周（P<0.0001）;第3剂后4周均明显高于第2剂后4周（P<0.0001）。结论 接种2剂新冠灭活疫苗可以产生较多数量的中和抗体和IgG抗体以发挥免疫效果,增加第3剂加强针后可以明显升高二者峰值。

关键词: 新型冠状病毒, 疫苗, 中和抗体, IgG, 免疫, 真实世界研究

Abstract: Objective To study the immunogenicity and related factors of the 3 doses inactivated SARS-CoV-2 vaccine. Method People who received 3 doses of inactivated SARS-CoV-2 vaccine in Nanchang Ninth Hospital from December 2020 to October 2021 were selected, At 3 weeks after the first dose, 4 weeks,16 weeks and 32 weeks after the second dose, and 4 weeks after the third dose, the blood neutralizing antibody, IgG and IgM antibody were detected respectively. Result A total of 874 participants were enrolled, including 316 males and 558 females. The positive rates of neutralizing antibody were 26.2%, 86.6%, 74.2%, 78.2% and 98.1% respectively at 3 weeks after the first dose, 4 weeks, 16 weeks, 32 weeks after the second dose and 4 weeks after the third dose;The positive rates of IgG antibody were 25.1%, 93.2%, 59.3%, 45.7% and 96.8% respectively. The quantitation of neutralizing antibody and IgG antibody at 4,16,32 weeks after the second dose and 4 weeks after the third dose were significantly higher than those at 3 weeks after the first dose (P<0.0001); 16,32 weeks after the second dose were significantly lower than 4 weeks after the second dose (P<0.0001); 4 weeks after the third dose were significantly higher than 4 weeks after the second dose (P<0.0001). Conclusion Two doses of the inactivated SARS-CoV-2 vaccine can produce a large number of neutralizing and IgG antibodies to play the immune effect, and the addition of the third dose of booster can significantly increase the peak value of both.

Key words: Severe acute respiratory syndrome coronavirus 2, Vaccine, Neutralizing antibody, Immuno globulin G, Immunogenicity, Real-world study

中图分类号: 

本系统由北京玛格泰克科技发展有限公司设计开发 技术支持：support@magtech.com.cn